ATE477811T1 - Oxytocin zur behandlung von autismus und asperger-syndrom - Google Patents

Oxytocin zur behandlung von autismus und asperger-syndrom

Info

Publication number
ATE477811T1
ATE477811T1 AT03770645T AT03770645T ATE477811T1 AT E477811 T1 ATE477811 T1 AT E477811T1 AT 03770645 T AT03770645 T AT 03770645T AT 03770645 T AT03770645 T AT 03770645T AT E477811 T1 ATE477811 T1 AT E477811T1
Authority
AT
Austria
Prior art keywords
oxytocin
autism
analogs
methods
asperger
Prior art date
Application number
AT03770645T
Other languages
English (en)
Inventor
Eric Hollander
Original Assignee
Neuropharmacology Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropharmacology Services Llc filed Critical Neuropharmacology Services Llc
Application granted granted Critical
Publication of ATE477811T1 publication Critical patent/ATE477811T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
AT03770645T 2002-10-03 2003-10-03 Oxytocin zur behandlung von autismus und asperger-syndrom ATE477811T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41583702P 2002-10-03 2002-10-03
PCT/US2003/031493 WO2004030524A2 (en) 2002-10-03 2003-10-03 Treatment of autism and similar disorders

Publications (1)

Publication Number Publication Date
ATE477811T1 true ATE477811T1 (de) 2010-09-15

Family

ID=32069910

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03770645T ATE477811T1 (de) 2002-10-03 2003-10-03 Oxytocin zur behandlung von autismus und asperger-syndrom

Country Status (9)

Country Link
US (1) US9662371B2 (de)
EP (1) EP1556068B1 (de)
CN (1) CN1711101A (de)
AT (1) ATE477811T1 (de)
AU (2) AU2003279137A1 (de)
CA (1) CA2500831A1 (de)
DE (1) DE60333857D1 (de)
ES (1) ES2353690T3 (de)
WO (1) WO2004030524A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2353690T3 (es) 2002-10-03 2011-03-04 Neuropharmacology Services, Llc Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger.
US7884076B2 (en) * 2003-11-06 2011-02-08 The Trustees Of Columbia University In The City Of New York Multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders
JO2937B1 (en) 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
KR100950737B1 (ko) 2005-08-24 2010-03-31 에자이 알앤드디 매니지먼트 가부시키가이샤 신규 피리딘 유도체 및 피리미딘 유도체(3)
RU2415149C2 (ru) 2006-02-10 2011-03-27 Ферринг Б.В. Пептидные соединения
JP5190365B2 (ja) 2006-08-23 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 フェノキシピリジン誘導体の塩またはその結晶およびそれらの製造方法
WO2008059991A1 (fr) 2006-11-15 2008-05-22 National University Corporation Kanazawa University Diagnostic et traitement de l'autisme en utilisant cd38
EP2175874A2 (de) 2007-08-14 2010-04-21 Ferring B.V. Verwendung von peptidischen vasopressin-rezeptoragonisten
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
WO2011027060A2 (fr) 2009-09-04 2011-03-10 Centre National De La Recherche Scientifique - Crns - Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
CA2774963A1 (en) * 2009-10-09 2011-04-14 Prothera, Inc. Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease
EP2544688B1 (de) 2010-03-02 2016-09-07 President and Fellows of Harvard College Verfahren und zusammensetzungen zur behandlung des angelman-syndroms
US20130130985A1 (en) * 2010-04-01 2013-05-23 Paul Alewood Oxytocin peptide analogues
WO2011146726A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
JO3400B1 (ar) 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
EA201590349A1 (ru) 2012-08-06 2015-07-30 С1 Биофарма, Инк. Режимы лечения
JP6304744B2 (ja) * 2013-12-20 2018-04-04 国立大学法人福井大学 愛着障害治療剤
PT3242676T (pt) 2015-01-07 2023-12-06 TONIX Pharmaceuticals Holding Corp Formulações de ocitocina que contém magnésio e métodos de uso
KR101815348B1 (ko) * 2015-05-06 2018-01-08 인제대학교 산학협력단 폭식성 섭식장애 조절을 위한 옥시토신의 용도
CA3020179A1 (en) * 2016-04-12 2017-10-19 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
PL3442547T3 (pl) 2016-04-15 2023-10-23 Baylor College Of Medicine Lactobacillus reuteri mm4-1a do zastosowania w leczeniu lub profilaktyce zaburzeń ze spektrum autyzmu
CA3196923A1 (en) * 2020-09-30 2022-04-07 Baylor College Of Medicine Oxytocin treatment for hypermobile ehlers-danlos syndrome
WO2022147251A1 (en) * 2020-12-30 2022-07-07 The General Hospital Corporation Methods and composition for the treatment of autism spectrum disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229880A1 (de) * 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
SE9701161D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
EP1095154A2 (de) 1998-07-10 2001-05-02 Curagen Corporation Interaktion von menschlichem beta-amyloid-protein (beta-app) mit menschlichem lon-protease (hslon)
US20070032410A1 (en) * 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
FR2807038B1 (fr) * 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
US6673790B1 (en) * 2000-04-03 2004-01-06 Sanofi-Synthelabo Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
EP1283055A4 (de) 2000-04-07 2003-05-07 Takeda Chemical Industries Ltd Lösliche promotoren der sekretion von beta amyloid protein vorläufer
WO2001085959A2 (en) 2000-05-12 2001-11-15 Bayer Aktiengesellschaft Regulation of human lysostaphin-like protease
ES2353690T3 (es) 2002-10-03 2011-03-04 Neuropharmacology Services, Llc Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger.
US20030166600A1 (en) * 2002-11-20 2003-09-04 Shyam Ramakrishnan Regulation of human isotocin-like g protein-coupled receptor

Also Published As

Publication number Publication date
AU2003279137A1 (en) 2004-04-23
ES2353690T3 (es) 2011-03-04
US20060105939A1 (en) 2006-05-18
CA2500831A1 (en) 2004-04-15
EP1556068A4 (de) 2008-01-02
CN1711101A (zh) 2005-12-21
WO2004030524A3 (en) 2004-06-10
EP1556068A2 (de) 2005-07-27
EP1556068B1 (de) 2010-08-18
WO2004030524A2 (en) 2004-04-15
DE60333857D1 (de) 2010-09-30
AU2009202043A1 (en) 2009-06-18
US9662371B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
ATE477811T1 (de) Oxytocin zur behandlung von autismus und asperger-syndrom
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE410157T1 (de) Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivität
ATE510542T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
ATE328588T1 (de) Behandlung von nicotinsucht und sucht bedingtem verhalten
ATE452652T1 (de) Behandlung neurologischer und neuropsychiatrischer erkrankungen mit botulinumtoxin
ATE552837T1 (de) Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
JP2020186274A5 (de)
DE60237158D1 (de) Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
DE60019106D1 (de) Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
Lee et al. Effects of computer-assisted cognitive rehabilitation training on the cognition and static balance of the elderly
TW200511996A (en) The use of steroids to treat persons suffering from ocular disorders
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
GARDNER et al. Interruption of the Sympathetic Nerve Supply to the Brain—Effect on Parkinson's Syndrome
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
BR0317772A (pt) Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento
Haque et al. Effects of Various Factors on Maxillary Arch Dimensions in Unilateral Cleft Lip and Palate Children: A Multi-population Study
ATE380884T1 (de) Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
Winkler Neurology, neurosurgery and psychiatry
TH124101B (th) องค์ประกอบที่ประกอบด้วยโมแดฟินิลสำหรับการรักษาแอทเทนชัน เดฟิซิท ไฮเปอร์แอกทิวิตี้ ดิสออร์เดอร์และความล้าเหตุมัลติเพิลสคลีโรซีส

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties